Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Tiziana Life Sciences Ltd (NQ: TLSA ) 0.9100 +0.0120 (+1.34%) Streaming Delayed Price Updated: 3:59 PM EST, Nov 7, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Tiziana Life Sciences Ltd < Previous 1 2 3 4 5 6 7 8 Next > Tiziana Life Sciences to Pursue Development of Intranasal Foralumab for the Treatment of Long COVID April 13, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire EXCLUSIVE: Tiziana Life Sciences Plans To Develop Multiple Sclerosis Hopeful For Long COVID Patients April 13, 2023 Tiziana Life Sciences Ltd (NASDAQ: TLSA) plans to investigate intranasal foralumab for Long COVID. What Happened: The work is supported by foralumab's well-established role in de-activating microglia... Via Benzinga Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences' (NASDAQ: TLSA) First-In-Class Foralumab Is Showing Promise April 12, 2023 Research is being done into whether there might be treatments that tackle Multiple Sclerosis (MS) through immunosuppression and a reduction of patient neuroinflammation. Anti-CD3 monoclonal antibodies... Via Benzinga NIO Could Bring A Pleasant Beat This Coming Quarter April 10, 2023 Tesla's price cuts have initiated a full on war across the EV industry, however NIO has refused to follow along. This may present even more upside for the stock Via MarketBeat Topics Electric Vehicles Exposures Electric Vehicles Tiziana Life Sciences Announces Presentations on Intranasal Foralumab at the “Preserving the Brain” Scientific Conference and Exhibit at Prada Rong Zhai in Shanghai April 10, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Announces Invitation for Podium Presentation of Research on Intranasal Anti-CD3 mAb in Intracerebral Hemorrhage at the Annual American Academy of Neurology Conference April 04, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Announces Positive Data on Intranasal Anti-CD3 Monoclonal Antibody in Intracerebral Hemorrhage April 04, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Announces Anti-CD3 mAb Research for the Treatment of Alzheimer’s Disease to be Presented by Dr. Howard Weiner at the International Conference on Alzheimer’s and Parkinson’s Disease and Related Neurological Disorders Conference in March 31, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Receives Sign-Off From The FDA To Proceed With Phase 2 Clinical Trial In Patients With Non-Active Secondary Progressive Multiple Sclerosis (SPMS) March 29, 2023 Tiziana Life Sciences Ltd. (NASDAQ: TLSA) announced it has received feedback based on the U.S. Food and Drug Administration (FDA) Type C meeting minutes related to the Phase 2 clinical trial of... Via Benzinga Tiziana Life Sciences to Proceed with Phase 2 Clinical Trial in Patients with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) March 28, 2023 FDA Provides Positive Feedback on Intranasal Foralumab Program in Patients with Non-Active SPMS From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO March 22, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO March 21, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO March 20, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Announces Purchase of Common Shares by Chairman and Acting CEO March 17, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Highlighted in Forbes Article March 17, 2023 Article entitled "New T Cell Antibody Treatment Improves Outcomes For Covid Patients" reviews the company's first in class foralumab, a unique Intranasal monoclonal antibody designed to treat multiple... From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Announces Publication in Proceedings of the National Academy of Sciences (PNAS) Illustrating the Immunological Basis of the Mechanism of Action for Intranasal Foralumab March 08, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire 7 Thrilling Stocks to Buy for Aggressive Investors March 06, 2023 Sometimes you need to be aggressive to unlock the best returns for your portfolio. Just be smart when looking for the best stocks to buy. Via InvestorPlace Proactive research analyst says Tiziana Life Sciences "moving forward quite nicely" February 09, 2023 Proactive research analyst says Tiziana Life Sciences "moving forward quite nicely" Via News Direct Proactive research analyst says Tiziana Life Sciences "moving forward quite nicely" February 09, 2023 Proactive research analyst Robin Davison speaks to Thomas Warner after publishing a 2023 Clinical Outlook for clinical stage biotechnology company Tiziana Life Sciences Ltd (NASDAQ:TLSA). He gives his... Via TheNewswire.com Tesla HODLs Bitcoin — But Sticks To Dogecoin-Only Crypto Payments Policy January 26, 2023 Electric car maker Tesla Inc (NASDAQ: TLSA) continues to hold on to Bitcoin (CRYPTO: BTC) but only accepts Dogecoin (CRYPTO: Via Benzinga Tiziana Life Sciences Announces IND filed for Phase 2 Study of Milciclib in Combination with Gemcitabine for Non-Small Cell Lung Cancer January 04, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Posts Additional Clinical Improvements In Second Patient with Multiple Sclerosis January 03, 2023 Via Benzinga Tiziana Life Sciences Announces Additional Clinical Improvements in the Second Patient with Non-Active Secondary Progressive Multiple Sclerosis (SPMS) After Eleven Months of Dosing with Intranasal Foralumab January 03, 2023 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Updated Interim Results for the Six Months Ended 30 June 2022 December 29, 2022 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Interim Results for the Six Months Ended 30 June 2022 December 27, 2022 Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana to Participate in January Investor Meetings December 16, 2022 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Announces Completion of Prerequisite Pre-Clinical Safety Study December 15, 2022 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Ltd. Granted 180-day Extension by Nasdaq to Meet Minimum Bid Price Requirements December 14, 2022 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Life Sciences Announces Date of Annual General Meeting 2022 December 06, 2022 From Tiziana Life Sciences Ltd. Via GlobeNewswire Tiziana Announces Publication of a Peer-Reviewed Article on the Intranasal Administration of Foralumab Demonstrating Modulated Effector CD8+ T cell Function and an Induced T Cell Regulatory Response in Human Subjects November 23, 2022 From Tiziana Life Sciences Ltd. Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
